Fritextsökning
Innehållstyper
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study...
-
Age essential when testing drugs
Anders Rane has been arguing that genes and age are both important factors in understanding how medicines affect individuals. Only last year, the EU established...
-
Elekta gets ok from China
The Swedish medtech comapny Elekta has received approval from the Chinese authority State Food and Drug Administration, SFDA, to sell its linear accelerator in China.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Crafoord Prize to an American and two Japanese
Today the Royal Swedish Academy of Sciences announces the laureates of the Crafoord Prize in Polyarthritis 2009.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Medicult disclaims Swedish offer
The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.
-
Svensk-danskt event blir e-möte
I september anordnas Life Science Swedens två event The Future of Swedish & Danish Life Science och New Updates in Drug Formulation & Bioavailability för första...
-
Collaboration brings next generation drugs
Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.
-
A platform for dialogue
As a step towards connecting the life science industry in Denmark, Biologue was founded three years ago with 10 member companies. Today, the network has 40 memb...
-
Acadia drug awarded
Acadia Pharmaceutical has got an award for a new treatment against Parkinson's disease.
-
Årets opinionsartiklar
Missa inte de opinionsartiklar som har blivit mest lästa i Life Science Sweden.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Galderma bygger nytt
Planerar ny tillverkningsanläggning i Uppsala och visar upp lovande resultat från studie med ready to use-lösning av botulinumtoxin.
-
Anna Törner: Dags att ta av de rosa glasögonen
”Förhoppningsvis har vi snart situationen under kontroll i många europeiska länder, men ur ett globalt perspektiv så är försvinnande få människor vaccinerade. V...
-
Tre gånger så många har dött av covid-19 enligt ny studie
18 miljoner människor – så många kan ha dött under pandemin, säger forskare bakom ny stor internationell studie. Det är tredubbelt fler än vad som tidigare rapp...
-
Ny kunskap om sällsynt grundämne
Forskare från Göteborgs universitet har lyckats skapa små mängder av världens mest sällsynta grundämne.
-
Apoteket gets new vice CEO
The Swedish government company Apoteket has recently appointed a vice CEO.
-
Fewer visitors but satisfied exhibitors
Biotech Forum Scanlab attracted fewer visitors than in 2008. Exhibition manager Bo Rasmussen is content, claiming that the exhibitors are very satisfied.
-
New map of eye proteins
A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.
-
Pfizer drar tillbaka artiklar
Utredning visar att sex artiklar om onkologi från läkemedelsjätten Pfizer innehåller förfalskade data. En av personerna bakom forskningen har lämnat bolaget.
-
LabDays tillbaka i Stockholm igen i april
50-tal utställare på fackmässan som är tillbaka med full kraft efter pandemin.